| [1] |
Yamada R，Sato M，Kawabata M，et al. Hepatic artery embolization in 120 patients with unresectable hepatoma[J]. Radiology，1983，148（2）:397-401.
|
| [2] |
Llovet JM，Real MI，Montaña X，et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet，2002，359（9319）:1734-1739.
|
| [3] |
Lo CM，Ngan H，Tso WK，et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology，2002，35（5）:1164-1171.
|
| [4] |
Llovet JM，Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J]. Hepatology，2003，37（2）:429-442.
|
| [5] |
Cammà C，Schepis F，Orlando A，et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials[J]. Radiology，2002，224（1）:47-54.
|
| [6] |
Takayasu K，Arii S，Ikai I，et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients[J]. Gastroenterology，2006，131（2）:461-469.
|
| [7] |
Ikeda M，Arai Y，Park SJ，et al. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea[J]. J Vasc Interv Radiol，2013，24（4）:490-500.
|
| [8] |
Oliveri RS，Wetterslev J，Gluud C. Transarterial（chemo）embolisation for unresectable hepatocellular carcinoma[J]. Cochrane Database Syst Rev，2011（3）: CD004787.
|
| [9] |
Rose SC，Kikolski SG，Gish RG，et al. Society of Interventional Radiology critique and commentary on the Cochrane report on transarterial chemoembolization[J]. Hepatology，2013，57（4）:1675-1676.
|
| [10] |
Forner A，Llovet JM，Bruix J. Chemoembolization for intermediate HCC: is there proof of survival benefit?[J]. J Hepatol，2012，56（4）:984-986.
|
| [11] |
Doffoël M，Bonnetain F，Bouché O，et al. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients（Federation Francophone de Cancerologie Digestive 9402）[J]. Eur J Cancer，2008，44（4）:528-538.
|
| [12] |
Akamatsu M，Yoshida H，Obi S，et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial[J]. Liver Int，2004，24（6）:625-629.
|
| [13] |
Pelletier G，Roche A，Ink O，et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma[J]. J Hepatol，1990，11（2）:181-184.
|
| [14] |
Raoul JL，Sangro B，Forner A，et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization[J]. Cancer Treat Rev，2011，37（3）:212-220.
|
| [15] |
Facciorusso A，Licinio R，Muscatiello N，et al. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients[J]. World J Hepatol，2015，7（16）:2009-2019.
|
| [16] |
Clavien PA，Lesurtel M，Bossuyt PM，et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncol，2012，13（1）:e11-e22.
|
| [17] |
Pinter M，Hucke F，Graziadei I，et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib[J]. Radiology，2012，263（2）:590-599.
|
| [18] |
中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范（2017年版）[J].中华消化外科杂志，2017，16（7）:635-646.
|
| [19] |
Irie T，Kuramochi M，Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure[J]. Cardiovasc Intervent Radiol，2013，36（3）:706-713.
|
| [20] |
Maruyama M，Yoshizako T，Nakamura T，et al. Initial experience with balloon-occluded trans-catheter arterial chemoembolization （B-TACE）for hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol，2016，39（3）:359-366.
|
| [21] |
Blanchard RJ，Lafave JW，Kim YS，et al. Treatment of patients with advanced cancer utilizing 90Y microspheres[J]. Cancer，1965，18:375-380.
|
| [22] |
Ariel IM. Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes（90Y radiating microspheres）[J]. Ann Surg，1965，162:267-278.
|
| [23] |
Mahnken AH. Current status of transarterial radioembolization[J]. World J Radiol，2016，8（5）:449-459.
|
| [24] |
Kim DY，Han KH. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality[J]. Hepatol Int，2016，10（6）:883-892.
|
| [25] |
杨雪玲，于海鹏，郭志.载药微球在肝癌经动脉化疗栓塞治疗中的应用研究新进展[J].中华医学杂志，2016（7）:589-592.
|
| [26] |
Han S，Zhang X，Zou L，et al. Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis[J]. PLoS One，2014，9（8）:e102686.
|
| [27] |
Kodama Y，Matsui T，Tsuji K，et al. Is drug-eluting bead transcatheter arterial chemoembolization（TACE）associated with better tumor response than conventional TACE in meta-analysis?[J]. Hepatol Res，2015，45（12）:1258-1259.
|
| [28] |
陈敏华.肝癌规范化消融治疗及进展[J].肝癌电子杂志，2014（1）:34-39.
|
| [29] |
Chang L，Wang Y，Zhang J，et al. The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies[J]. Oncotarget，2017，8（12）:20418-20427.
|
| [30] |
Nishikawa H，Kita R，Kimura T，et al. Transcatheter arterial embolic therapies for hepatocellular carcinoma: a literature review[J]. Anticancer Res，2014，34（12）:6877-6886.
|
| [31] |
Seehofer D，Nebrig M，Denecke T，et al. Impact of neoadjuvant transarterial chemoembolization on tumor recurrence and patient survival after liver transplantation for hepatocellular carcinoma: a retrospective analysis[J]. Clin Transplant，2012，26（5）:764-774.
|
| [32] |
邹英华，吕天石.肝动脉化疗栓塞术（TACE）联合射频消融术（RFA）治疗原发性肝癌研究进展[J].肝癌电子杂志，2014（1）:29-33.
|
| [33] |
Wang X，Hu Y，Ren M，et al. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: A time-to-event meta-analysis[J]. Korean J Radiol，2016，17（1）:93-102.
|
| [34] |
Yang DJ，Luo KL，Liu H，et al. Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma[J]. Oncotarget，2017，8（2）:2960-2970.
|
| [35] |
Pung L，Ahmad M，Mueller K，et al. The role of cone-beam CT in transcatheter arterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis[J]. J Vasc Interv Radiol，2017，28（3）:334-341.
|
| [36] |
Kang SG，Yoon CJ，Jeong SH，et al. Single-session combined therapy with chemoembolization and radiofrequency ablation in hepatocellular carcinoma less than or equal to 5 cm: a preliminary study[J]. J Vasc Interv Radiol，2009，20（12）:1570-1577.
|
| [37] |
Wang ZJ，Wang MQ，Duan F，et al. Transcatheter arterial chemoembolization followed by immediate radiofrequency ablation for large solitary hepatocellular carcinomas[J]. World J Gastroenterol，2013，19（26）:4192-4199.
|
| [38] |
Si ZM，Wang GZ，Qian S，et al. Combination therapies in the management of large（≥ 5 cm）hepatocellular carcinoma: microwave ablation immediately followed by transarterial chemoembolization[J]. J Vasc Interv Radiol，2016，27（10）:1577-1583.
|
| [39] |
Di Marco V，De Vita F，Koskinas J，et al. Sorafenib: from literature to clinical practice[J]. Ann Oncol，2013，24（Suppl 2）: ii30-37.
|
| [40] |
Kelley RK. Adjuvant sorafenib for liver cancer: wrong stage，wrong dose[J]. Lancet Oncol，2015，16（13）:1279-1281.
|
| [41] |
Abou-Alfa GK. TACE and sorafenib: a good marriage?[J]. J Clin Oncol，2011，29（30）:3949-3952.
|
| [42] |
Chao Y，Chung YH，Han G，et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial[J]. Int J Cancer，2015，136（6）:1458-1467.
|
| [43] |
Lencioni R，Llovet JM，Han G，et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial[J]. J Hepatol，2016，64（5）:1090-1098.
|